MAPT and Alzheimer disease: Our results also showed that two of the four SCD‐plus features (i.e., SMD and an associated concern/worry) are sensitive to abnormal Aβ levels, whereas the simultaneous endorsement of multiple SCD‐plus features is a robust indicator of preclinical AD (i.e., abnormally elevated Aβ and tau levels).